

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

## EQA round: RFA1/21 - Risk Factors for Atherosclerosis

Deadline: 09.04.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(111) Cholesterol</b>					40							40	37	93%
--- Samples and groups	[mmol/L]													
<b>Sample A</b>		3,75	0,15	4,0	40	CVP	3,74	0,017	8%	3,44	4,04	40	39	98%
(1) Enzyme method CHOD-PAP		3,75	0,15	4,0	40	0						40		
<b>Sample B</b>		7,97	0,33	4,1	40	CVP	7,92	0,041	8%	7,28	8,56	40	37	93%
(1) Enzyme method CHOD-PAP		7,97	0,33	4,1	40	0						40		
<b>(112) Triacylglycerols</b>					40							40	40	100%
--- Samples and groups	[mmol/L]													
<b>Sample A</b>		1,18	0,043	3,6	40	CVP	1,18	,0064	15%	1	1,36	40	40	100%
(1) Photometric enzyme (GPO-PAP)		1,18	0,037	3,1	37	0						37		
Other					3	0						3		
<b>Sample B</b>		2,41	0,074	3,1	40	CVP	2,42	,0091	15%	2,05	2,79	40	40	100%
(1) Photometric enzyme (GPO-PAP)		2,42	0,073	3,0	37	0						37		
Other					3	0						3		
<b>(113) Cholesterol HDL</b>					40							40	38	95%
--- Samples and groups	[mmol/L]													
<b>Sample A</b>		0,998	0,04	4,0	40	CVP	0,998	,0061	15%	0,848	1,15	40	38	95%
(2) Direct determination		0,999	0,041	4,1	39	0						39		
Other					1	0						1		
<b>Sample B</b>		2,16	0,11	5,0	40	CVP	2,17	0,013	15%	1,84	2,5	40	39	98%
(2) Direct determination		2,16	0,11	5,1	39	0						39		
Other					1	0						1		
<b>(114) Apolipoprotein AI</b>					11							11	11	100%
--- Samples and groups	[g/L]													
<b>Sample A</b>		1,18	0,083	7,0	11	CVP	1,15	0,016	21%	0,908	1,4	11	11	100%
(2) Immunoturbidimetry		1,19	0,087	7,4	10	0						10		
Other					1	0						1		
<b>Sample B</b>		2,30	0,22	9,4	11	CVP	2,38	0,046	21%	1,88	2,88	11	11	100%
(2) Immunoturbidimetry		2,33	0,21	8,9	10	0						10		
Other					1	0						1		
<b>(115) Apolipoprotein B</b>					14							14	13	93%
--- Samples and groups	[g/L]													
<b>Sample A</b>		0,716	0,052	7,3	14	CVP	0,718	,0081	18%	0,588	0,848	14	13	93%
(2) Immunoturbidimetry		0,725	0,035	4,9	13	0						13		
Other					1	0						1		
<b>Sample B</b>		1,46	0,11	7,7	14	CVP	1,49	0,021	18%	1,22	1,76	14	14	100%
(2) Immunoturbidimetry		1,47	0,11	7,6	13	0						13		
Other					1	0						1		
<b>(116) Cholesterol LDL (calculation)</b>					14							14	13	93%
--- Samples and groups	[mmol/L]													
<b>Sample A</b>		2,22	0,13	5,7	14	CVP	2,23	0,027	15%	1,89	2,57	14	13	93%
(0) Not specified		2,22	0,13	5,7	14	0						14		
<b>Sample B</b>		4,81	0,24	5,1	14	CVP	4,71	0,054	15%	4	5,42	14	14	100%
(0) Not specified		4,81	0,24	5,1	14	0						14		
<b>(118) Cholesterol LDL (direct determ.)</b>					33							33	32	97%
--- Samples and groups	[mmol/L]													
<b>Sample A</b>		2,34	0,15	6,5	33	CVP	2,32	0,027	15%	1,97	2,67	33	32	97%
(0) Not specified		2,34	0,15	6,5	33	0						33		
<b>Sample B</b>		4,92	0,37	7,4	33	CVP	4,92	0,066	15%	4,18	5,66	33	32	97%
(0) Not specified		4,92	0,37	7,4	33	0						33		
<b>(117) Lipoprotein (a) [g/L]</b>					7							7	7	100%
--- Samples and groups	[g/L]													
<b>Sample A</b>		0,155	0,037	24	7	CVP	0,179	,0076	32%	0,121	0,237	7	7	100%
(2) Immunoturbidimetry		0,170	0,015	8,7	5	0						5		
Other					2	0						2		
<b>Sample B</b>		0,357	0,079	22	7	CVP	0,39	,0100	32%	0,265	0,515	7	7	100%

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of the groups n = 5

## EQA round: RFA1/21 - Risk Factors for Atherosclerosis

Deadline: 09.04.2021

Test	[unit]	RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	Comparability							
							AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(117) Lipoprotein (a) [g/L]</b>	[g/L]				7							7	7	100%
Samples and groups														
<b>Sample B</b>		0,357	0,079	22	7		CVP	0,39	0,0100	32%	0,265	0,515	7	7 100%
(2) Immunoturbidimetry		0,385	0,037	9,6	5	0							5	
Other					2	0							2	
							1x 0, 1x 3							
<b>(119) Lipoprotein (a) [nmol/L]</b>	[nmol/L]				2							2	2	100%
Samples and groups														
<b>Sample A</b>		27,7	1,4	5,1	2		CVP	31,8	1,4	20%	25,4	38,2	2	2 100%
Other					2	0							2	
							2x 2							
<b>Sample B</b>		71,2	3,5	4,9	2		CVP	78,5	2,0	20%	62,8	94,2	2	2 100%
Other					2	0							2	
							2x 2							
st_kn_p							End of report							Printed: 20.04.2021